SRR4296070
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 89
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518413 | — | F | 0.892 |
| 2 | TCGA-CU-A5W6-01A-11R-A28M-07 | — | — | 0.892 |
| 3 | MBCProject_3946_T5A_RNA | — | C | 0.852 |
| 4 | TCGA-B6-A0IA-01A-11R-A034-07 | — | B | 0.844 |
| 5 | TCGA-D8-A1JS-01A-11R-A13Q-07 | — | B | 0.842 |
| 6 | TCGA-C8-A133-01A-32R-A12D-07 | — | B | 0.839 |
| 7 | TCGA-A8-A07P-01A-11R-A00Z-07 | — | B | 0.827 |
| 8 | TCGA-49-4486-01A-01R-1206-07 | — | cohortA2 | 0.821 |
| 9 | TCGA-B6-A0RO-01A-22R-A084-07 | — | C | 0.818 |
| 10 | SRR1471817 | GTEX | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |